Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study confirms link between breast density, higher breast cancer risk

2.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

3.

How a California Oncologist Making $850k Spends Money

4.

Data indicate 1 in 3 US adults unaware of connection between HPV and cancers

5.

A new therapeutic approach could help tackle radiation resistance in childhood brain tumors


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot